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Background: This study aims to identify factors associated with health related quality of life (HRQOL) through a
comprehensive analysis of sociodemographic and clinical variables among a representative sample size of renal
transplant recipients (RTR) in France.
Methods: A cross-sectional multicenter study was carried out in 2008. All RTR over 18 years old with a functioning
graft for at least one year were included. Data included socio-demographic, health status, and treatment
characteristics. To evaluate HRQOL, the Short Form-36 Health Survey (SF-36) and a HRQOL instrument for RTR
(ReTransQol) were administered. Multivariate linear regression models were performed.
Results: A total of 1061 RTR were included, with a return rate of 72.5%. The variance explained in regression
models of SF-36 ranges from 20% to 40% and from 9% to 33% for ReTransQol.
The variables which decreased scores of both HRQOL questionnaires were: females, unemployment, lower
education, living alone, high BMI, diabetes, recent critical illness and hospitalization, non-compliance, a long
duration of dialysis and treatment side effects.
Specific variables which decreased ReTransQol scores were dismissal and a recent surgery on the graft. These which
decreased SF36 scores were being old and a recent infectious disease.
The variables the most predictors of worse HRQOL were: side effects, infectious disease, recent hospitalization and
female gender.
Conclusions: The originality of our study’s findings was that novel variables, particularly treatment side effects and
unemployment, have a negative effect on quality of life of RTR. The French Biomedicine Agency and the National
Health Institute for Public Health Surveillance conduct specific actions for professional reintegration and therapeutic
education programs in the national plan to improve the HRQOL of people living with chronic diseases.
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In public health and in medicine, the concept of health-
related quality of life (HRQOL) is defined as an individ-
ual’s perception of their position in life in the context of
the culture and value systems in which they live and in
relation to their goals, expectations, standards and con-
cerns [1]. Physicians have often used HRQOL to meas-
ure the effects of chronic illness in their patients to
better understand how an illness interferes with a per-
son’s day-to-day life [2,3].
Although the HRQOL advantages of renal transplant-
ation are well established [4-8], large differences of qual-
ity of life are often observed depending on specific
transplant cohorts [9,10]. Life after renal transplantation
presents negative aspects as well, such as a strict regi-
men of immunosuppressive drugs and its related side ef-
fects, frequent medical visits, infections, the uncertainty
and anxiety concerning rejection episodes and potential
loss of the graft [11-16]. Therefore, one of the most im-
portant issues for the future of transplantation is to
more clearly specify the full range of personal, environ-
mental and clinical factors that negatively influence
HRQOL outcomes. A better understanding of the role of
these factors is essential to develop interventions that
maximize the HRQOL in the context of transplantation.
The World Health Organization (WHO) prioritizes
HRQOL improvement for people living with chronic dis-
eases, End-stage renal disease patients were concerned by
a specific WHO program [17]. In France, the August 9,
2004 public health law applied this priority, implementing
a national plan to improve the HRQOL for people living
with chronic diseases [18]. The French Biomedicine
Agency and the National Institute for Public Health Sur-
veillance have promoted studies to determine the level of
HRQOL of end-stage renal disease patients in France, at
the start of the national plan to improve the HRQOL of
chronic disease patients [19,20].
In France, dialysis patients are followed-up through
the French Renal Epidemiology and Information Net-
work (REIN) [21]. REIN began in 2002 to provide a tool
for public health decision support, evaluation and
research related to renal replacement therapies for end-
stage renal disease. It relies on a network of nephrolo-
gists, epidemiologists, patients and public health represen-
tatives coordinated regionally and nationally. Moreover,
the renal transplant recipients (RTR) are registered in a
transplant database (CRISTAL) managed by the French
Biomedicine Agency [22], which collects social and med-
ical data for all patients who receive an organ transplant.
Both databases are updated regularly, and have been used
as sources of data for the end-stage renal disease specific
program to improve HRQOL.
Two separate studies planned as part of the “QUAVI-
REIN” (the French translation for Renal Quality of Life)multiregional projects have been performed in 8 of the
22 regions of France: one focusing on dialysis patients
[23], and the second focusing on RTR when data were
available for both populations. This study aims to iden-
tify factors associated with HRQOL through a comprehen-
sive analysis of sociodemographic and clinical variables
among a representative sample size of RTR in France.
Materials and methods
Data sources
A cross-sectional multicenter study was carried out in
France between March 2007 and March 2008, in the
eight regions of France participating in the REIN network
in 2003: Auvergne, Bretagne, Champagne-Ardennes,
Languedoc-Roussillon, Limousin, Lorraine, Provence-
Alpes-Côte d’Azur and Rhône-Alpes.
Participants
All RTR over 18 year of age with a functioning graft for
at least one year were eligible. Multi-organ transplant
patients before or simultaneously with their kidney
transplant were excluded. RTR and their addresses were
identified from the CRISTAL database. The sample was
stratified by regions and age class, using the same sam-
pling rate for each stratum. The sample size was calcu-
lated to detect a difference of 5 points in the Short
Form-36 Health Survey (SF-36) HRQOL score consider-
ing a standard deviation of 20, assuming a two-sided
level of 5% and 80% power. A maximum of four compar-
isons was scheduled. The sample size calculation was
1,000 patients. Considering a non-response rate of ap-
proximately 30%, 1,300 questionnaires were sent in
order to achieve 1,000 patients. We randomized an add-
itional sample of 500 patients in case the response rate
in some region or age class was not adequate. A total of
401 patients were not included: 155 were returned to
sender, 3 deceased patients and 243 were lost to follow-
up. Finally, 162 more questionnaires were sent to
complete a lack of data in some age class, reaching a
total of 1462 questionnaires sent in all 8 regions. The
number of self-administrated questionnaires returned
was 1061.
Measures
Data collection included demographic, socio-demographic,
medical characteristics and HRQOL. All data were
obtained directly from patients except their age, gender
and nephropathy, which were obtained from the CRISTAL
database.
Socio-demographic characteristics
Demographic variables assessed were gender, age, em-
ployment status (retirement, unemployment and work-
ing), education level (primary or less, secondary 1st
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(living alone versus other status) and dismissal due to ill-
ness (when an employer did a procedure for dismissing
a member of staff due to illness).Medical characteristics
Medical measures were grouped into three domains
related to kidney disease, health status, and treatment
(i.e. drugs, side effects and compliance).
1. Kidney disease: etiology of end-stage renal failure,
duration of dialysis, duration of transplantation and
graft rejection episodes.
2. Health status: comorbidities (i.e. hypertension,
Diabetes Mellitus), intercurrent health events during
the last four weeks, critical illness, especially
infectious disease, graft surgery, hospital admission,
Body Mass Index (BMI), and smoking status.
3. Treatment: to collect the drug treatments, we
established with nephrologists a selective list of the
most commonly prescribed drugs using their generic
names.
The patient could also add the medication if drugs
were not included in the list. Therapeutics data were
classified according to Anatomical Therapeutic and
Chemical (ATC) classification [24].
4. Side effects: to collect treatment side effects, we
used a list of 18 items identified by RTR [25]. The
patient rated the importance on a 4-level Likert
scale, ranging from “no discomfort” to “very
significant discomfort”.
Side effects were categorized into 5 domains according
to the following classification:
1. General health: muscular weaknesses, general
tiredness, pain, lower limb oedema, etc.
2. Mental Health: depression, anxiety, sleep disorders.
3. Body modification: facial changes, facial oedema,
weight gain, hair loss, swollen gums, brittle skin, etc.
4. Sexual dysfunctional
5. Diarrhea
Three items explored compliance:
 Difficulty to respect the immunosuppressant
schedule
 Modification of immunosuppressive therapy
 Modification of the dosage of treatments (other than
immunosuppressive therapy drugs)
Patients who answered “yes” to one of these three
items were categorized as non-compliant.Health-related quality of life
SF-36 [26] and ReTransQol [27] were used to evaluate
HRQOL.
The French version of the SF-36 is a generic instru-
ment, with scores ranging from 0 (complete dissatisfac-
tion) to 100 (full satisfaction) for eight domains: physical
functioning (PF), role-physical (RP), bodily pain (BP),
general health (GH), vitality (VT), social functioning
(SF), role-emotional (RE) and mental health (MH). The
correlated physical (PCS) and mental (MCS) summary
components were computed following the standardized
procedure provided by authors.
The ReTransQol is a specific instrument consisting of
45 items describing 5 dimensions: physical health (PH),
mental health (MH), medical care and satisfaction (MC),
treatment (TRT) and fear of losing graft (FG). Each
score ranges from 0 to 100, and the higher the score, the
better the perceived state of health [27].
Data collection procedures
All measurement instruments were sent to the patient’s
residence with a letter signed by the project coordinator.
Patients returned the completed questionnaires via a
pre-stamped envelope. Non-respondents were reminded
by a second letter three weeks later and contacted by
phone.
Ethical aspects
The study methodology was approved by the local Institu-
tional Review Board (CCTIRS n°06-311) and the “Comité
National Informatique et Liberté” (CNIL n°906248), which
ensures the confidentiality of all information collected.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation (SD) or range. Discrete variables were reported
as frequency and percentage. Group comparisons were
performed using analysis of variance (bivariate analysis).
All factors with a p-value <0.25 were included as candi-
date variables in a multivariate analyses, according to
the literature review.
Multivariate linear regression models (MLR) were
used to estimate the relationship between HRQOL
scores and socio-demographic, health status and treat-
ment characteristics.
Multivariate analysis was summarized by the β coeffi-
cients and their 95% confidence interval and p-value.
The R-squares were performed. The level of significance
was set at a p-value <0.05 (factors presented). Statistical
analysis was performed using SAS® 9.2 system software.
Results
At the time of the survey, there were 5,991 patients
present in the CRISTAL database living with a functional
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to a total of 1061 patients were obtained from 1462 sam-
pled, with a response rate of 72.5%.
Socio-demographic characteristics
The mean age of patients was 55.2 years (± 12.4 years)
and 61.8% were male. Nearly 80% of RTR lived as a
couple. Less than 40% of patients were employed at the
time of the survey. Among unemployed RTR, half were
retired. Patient characteristics are shown in Table 1.
Medical characteristics
Kidney disease: The mean time since transplantation
was 8.5 years (± 5.8 years, range 1–40). A total of 23.5%
of patients had at least one intercurrent health event in
the past four weeks (Table 2). Among this sample, 11.1%
(n = 111) had been hospitalized in the last four weeks,
4.7% (n = 47) had a critical illness, 13.7% (n = 123) had
an infectious disease, 4% (n = 42) had acute rejection ep-
isodes and 1.9% (n = 17) had a surgery on the graft in
the last four weeks.
Treatment
Most patients (89.3%) had two or three immunosuppres-
sive drugs. Nearly 84% of patients had antihypertensives,
51.2% had lipid lowering drugs and 9.5% antidiabetic
agents. Most of the patients (77.5%) were compliant. Diffi-
culty to respect the medication regimen was the main rea-
son for non-compliance. The majority of patients (79%)
reported treatment side effects, particularly those related
to body modification: 72.7% (n = 771). The mean number
of side effects was 5.7 ± 3.9 (range 1–17) (Table 2).
Health related quality of life
Table 3 shows mean HRQOL scores and SD correspond-
ing to the different dimensions of the SF-36 and
ReTransQol questionnaires used.Table 1 Socio-demographic characteristics
n %
Male 656 61.8%
Age, years (mean ± SD) 55.2 ± 12.4
Level of education
Primary or less 260 25.8%
Secondary 1st stage (college & high school) 483 48%
Higher than secondary, 2nd stage or university 264 26.2%
Living arrangement




Retired 118 31.4%Variables included the final regression model for both
HRQOL questionnaires
In SF-36 and ReTransQol models of regression, at least
16 and 14 variables, respectively, were included to
strengthen the model and obtain significant scores, with
a good variance explanation for each dimension. Ad-
justed differences in the eight generic scales of SF-36
and in the five specific dimensions of ReTransQol using
socio-demographic, medical and treatment variables are
shown in Tables 4 and 5. The variance explained in re-
gression models for SF-36 ranges from 20% to 40%
(Table 4) and from 9% to 33% for ReTransQol (Table 5).
Factors associated with a modification of HRQOL for SF-36
The variables which were associated with lower SF-36
scores were: older age, female gender, unemployment,
lower education, living alone, high BMI, diabetes, infec-
tious disease, critical illness and hospitalization in the
last 4 weeks, non-compliance, former smoker, a long
duration of dialysis, side effects related to general health
and mental health or body modification domains
(Table 4).
The five variables which contributed most to a worse
quality of life were: side effects related to general health and
mental health domains, infectious disease, hospitalization
in the last 4 weeks, and female gender (Figure 1). The
“potentially modifiable” variables are in bold and the
others are consider as “not likely modifiable” by inter-
vention programs.
Factors associated with a modification of HRQOL for
retransQOL
The following variables (Table 5) played a significant role
in the reduction of HRQOL using the ReTransQol sub-
scales: female gender, unemployment, dismissal, lower
education, living alone, high BMI, side effects related to
general health, mental health and body modification do-
mains, infectious disease, critical illness, hospitalization
in the last 4 weeks, non-compliant, a recent surgery on
the graft and a long duration of dialysis (Figure 2).
The four variables which were associated with a lower
quality of life are those associated to side effects related
to mental health, body modifications and general health
domains, and female gender.Discussion
We analyzed the factors associated with a lower qual-
ity of life in a representative sample of 1,061 renal trans-
plant recipients from 8 regions of France. This study is
the first report in France of HRQOL in kidney trans-
plantation with such a large sample of patients.
The sociodemographic characteristics of our sample
were similar to those reported in the literature [28-30].
Our sample is representative of general French RTR.
Moreover, there are few studies with extensive observa-
tions carried out. In our literature review, few studies
Table 2 Medical characteristics and treatments




Cadaveric donor transplantation 1035 97.5%
Duration of transplantation, years 8.5 ± 5.8
Patients with rejection since
renal transplant
222 22.9%
Major causes of ESRD
Chronic glomerular nephritis 380 35.8%
Interstitial nephropathy 122 11.5%
Hereditary nephropathy 206 19.4%
Duration of dialysis, months
(mean ± SD)
31.3 ± 37.2
Intercurrent health events in
the last four weeks
245 23.2%
Hospitalization 111 11.1%
Critical illness 47 4.7%
Infectious disease 123 13.7%
Acute rejection episodes 42 4.0%
Graft surgery 17 1.9%
Comorbidities
Hypertension 844 80.9%
BMI > 30 (kg/m2) 140 13.4%
Diabetes mellitus 133 12.9%
Current smokers 122 11.8%
Treatments,
compliance and side
Side effects 838 79%








Calcineurin inhibitors 956 90.6%
Corticosteroids 593 56.2%
Antimetabolites 769 72.9%





Antihypertensive drugs 890 84.4%
Hypolipidemics 540 51.2%
Antidiabetic agents 100 9.5%
Non-compliant to treatment 239 22.5%
Side effects related to:
General health 548 51.6%
Mental health 467 44.0%
Table 2 Medical characteristics and treatments
(compliance and side effects) (Continued)
Body modification 771 72.7%
Sexual disorders 288 27.1%
Diarrhea 216 20.4%
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the substantial sample size, the response rate of 72.8%,
and multivariate analysis are strengths of the present
study.
After an analyze of the literature review, the level of
quality of life of our patients may be different [4] as well
as similar [33-36], depending of the country of the study,
the sample size, the medical care or the Public Health
organization. In general, SF36 scores are slightly lower
than those found in the literature, probably because of
our big sample size of patients used compared with
other studies.
Another strong point of the current study was the
construction of a comprehensive multivariate model, in-
cluding several sociodemographic, clinical and treatment
variables in its adjusted analysis. The independent vari-
ables were selected based on a previous univariate ana-
lysis and from a literature review. The final regression
models explained 32% of the physical (PCS) HRQOL
variance and 23% of mental HRQOL variance (MCS).
Previous studies describe that use of highly effective pre-
dictive regression models only explained between 3%
and 22% of HRQOL variance among chronic renal dis-
ease patients [37,38].Table 3 HRQOL scores
Dimensions Means ± SD
S F - 3 6
Physical Functioning- PF 74.8 ± 24.3
Social Functioning- SF 74.9 ± 23.6
Role Physical- RP 64.4 ± 41.3
Role Emotional- RE 68.8 ± 41.3
Mental Health 65.5 ± 18.7
Vitality- VT 53.3 ± 19.3
Bodily Pain- BP 68.3 ± 25.8
General Heath- GH 55.4 ± 21
Physical Component Summary- PCS 45.8 ± 9.7
Mental Component Summary- MCS 46.0 ± 10.5
R e T r a n s Q o l
Physical Health - PH 63.8 ± 17.4
Mental Health - MH 72.6 ± 16.7
Medical Care - MC 75.0 ± 14.9
Fear of losing the Graft - FG 58.4 ± 20.4
Treatment - TRT 70.7 ± 13.9
Table 4 Final regression models (SF 36 domains)
Dimensions Variables β coeff. 95% CI P values
PF R2 = 0.31 Intercept 95.4 [91.1; 99.6] p < .0001
Female -4.7 [-7.6; -1.7] p < 0.0018
Age ≥ 75 years -23.3 [-30.4; -16.2] p < .0001
Low educational (primary or less) -7.5 [-11.2; -3.8] p < .0001
Unemployment -6.3 [-9.4; -3.2] p < .0001
BMI > 30 (kg/m2) -5.8 [-10; -1.6] p < 0.0065
Critical illness in the last 4 weeks -8.0 [-14.9; -1.1] p < 0.0237
Diabetes -5.6 [-10.1; -1] p < 0.0163
Side effects related to general health -17.0 [-20.9; -13.1] p < .0001
Side effects related to mental health -6.8 [-10.5; -3] p < 0.0004
Recent surgery -9.5 [-24.9; 6] p < 0.2283
Infectious disease in the last 4 weeks -4.8 [-9.1; -0.4] p < 0.0311
RP R2 = 0.22 Intercept 90.5 [82.8; 98.1] p < .0001
Female -6.9 [-12.2; -1.6] p < 0.0104
Age ≥ 75 years -20.1 [-33.1; -7] p < 0.0026
Low educational (primary or less) -11.4 [-18; -4.8] p < 0.0007
Hospitalization in the last 4 weeks -17.9 [-27.1; -8.8] p < 0.0001
Critical illness in the last 4 weeks -31.5 [-44.8; -18.1] p < .0001
Infectious disease in the last 4 weeks -10.9 [-19; -2.9] p < 0.0080
Side effects related to general health -21.5 [-28.7; -14.3] p < .0001
Side effects related to mental health -16.0 [-22.8; -9.1] p < .0001
BP R2 = 0.23 Intercept 85.3 [80.6; 90] p < .0001
Female -4.9 [-8.1; -1.6] p < 0.0035
Age ≥ 75 years -8.3 [-16.1; -0.4] p < 0.0402
Low educational (primary or less) -6.5 [-10.5; -2.5] p < 0.0016
Infectious disease in the last 4 weeks -9.1 [-14; -4.3] p < 0.0002
Side effects related to general health -18.7 [-23.2; -14.2] p < .0001
Side effects related to mental health -9.7 [-14; -5.4] p < .0001
Side effects related to body modification -4.2 [-7.7; -0.7] p < 0.0193
MH R2 = 0.24 Intercept 81.1 [77.7; 84.6] p < .0001
Female -5.6 [-8; -3.3] p < .0001
Family status (living alone) -4.6 [-7.2; -1.9] p < 0.0007
Duration of dialysis > 3 years -3.3 [-5.8; -0.8] p < 0.0087
Hospitalization in the last 4 weeks -7.7 [-11.4; -4] p < .0001
Side effects related to mental health -16.5 [-19.5; -13.5] p < .0001
Side effects related to body modification -4.4 [-6.9; -1.9] p < 0.0005
RE R2 = 0.18 Intercept 94.8 [86.5; 103] p < .0001
Female -6.4 [-12; -0.8] p < 0.0252
Low educational (primary or less) -16.8 [-24; -9.6] p < .0001
Age ≥ 75 years -11.1 [-25.3; 3.2] p < 0.1285
Family status (living alone) -9.1 [-15.3; -2.8] p < 0.0045
Hospitalization in the last 4 weeks -17.4 [-26.7; -8.1] p < 0.0003
Infectious disease in the last 4 weeks -19.1 [-27.6; -10.7] p < .0001
Side effects related to mental health -25.0 [-32; -18.1] p < .0001
Gentile et al. Health and Quality of Life Outcomes 2013, 11:88 Page 6 of 12
http://www.hqlo.com/content/11/1/88
Table 4 Final regression models (SF 36 domains) (Continued)
SF R2 = 0.25 Intercept 90.8 [86.8; 94.8] p < .0001
Female -4.9 [-7.6; -2.1] p < 0.0006
Family status (living alone) -4.6 [-7.8; -1.5] p < 0.0036
Hospitalization in the last 4 weeks -11.8 [-16.2; -7.3] p < .0001
Infectious disease in the last 4 weeks -7.2 [-11.5; -2.9] p < 0.0011
Diabetes -7.5 [-11.5; -3.5] p < 0.0002
Side effects related to general health -11.3 [-15; -7.6] p < .0001
Side effects related to mental health -16.4 [-20; -12.8] p < .0001
VT R2 = 0.22 Intercept 62.8 [59.6; 66.1] p < .0001
Female -2.4 [-4.6; -0.1] p < 0.0366
Hospitalization in the last 4 weeks -8.3 [-11.8; -4.8] p < .0001
Side effects related to general health -12 [-15; -8.9] p < .0001
Side effects related to mental health -11.7 [-14.8; -8.7] p < .0001
Side effects related to body modification -3.9 [-6.3; -1.4] p < 0.0020
GH R2 = 0.18 Intercept 63.8 [62.1; 65.5] p < .0001
Hospitalization in the last 4 weeks -6.1 [-10.2; -2] p < 0.0038
Critical illness in the last 4 weeks -7.1 [-13.5; -0.7] p < 0.0305
Diabetes -5.4 [-9; -1.7] p < 0.0038
Side effects related to general health -11.6 [-15.1; -8.1] p < .0001
Side effects related to mental health -7.7 [-11.1; -4.2] p < .0001
Side effects related to body modification -5.6 [-8.4; -2.9] p < .0001
Non-compliant -6.3 [-9.2; -3.4] p < .0001
PCS (R2 = 0.28) Intercept 52.7 [50.9; 54.5] p < .0001
Female -1.7 [-3; -0.4] p < 0.0084
Age ≥ 75 years -7.7 [-11; -4.3] p < .0001
Low educational (primary or less) -3.3 [-4.9; -1.7] p < .0001
Unemployment -2.5 [-3.8; -1.1] p < 0.0003
Critical illness in the last 4 weeks -5.7 [-8.8; -2.6] p < 0.0003
Infectious disease in the last 4 weeks -3.2 [-5.1; -1.3] p < 0.0012
Side effects related to general health -9.2 [-10.8; -7.5] p < .0001
MCS (R2 = 0.22) Intercept 52.1 [50.3; 54] p < .0001
Female -1.7 [-3; -0.4] p < 0.0113
Family status (living alone) -2.2 [-3.7; -0.7] p < 0.0039
Hospitalization in the last 4 weeks -5.7 [-7.8; -3.6] p < .0001
Side effects related to body modification -2.5 [-3.9; -1.1] p < 0.0005
Side effects related to mental health -9.3 [-11; -7.7] p < .0001
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HRQOL associated with a specific one. We applied the
generic instrument SF-36 Health Survey, the most used
questionnaire for HRQOL analysis in RTR [2,39,40] We
also associated a disease-specific instrument validated
for RTR in the French language: the ReTransQol [27].
In our study, quality of life scores were lower with all
the socio-demographic and health status variables col-
lected. The impact of socio-demographic variables isknown for having a negative influence on HRQOL.
These findings are in accordance with other studies:
level of HRQOL significantly decreases with age [41],
gender, living status and the educational level [34,42-44].
This study points out that unemployed patients have
an extremely impaired HRQOL, especially for physical
and mental dimensions, whatever the measurement in-
strument used [43,45]. This is why the French Biomedi-
cine Agency and the National Health Institute for Public
Table 5 Final regression models (ReTransQol domains)
Dimensions Variables Β coeff. 95% CI P values
PH R2 = 0.31 Intercept 78.2 [75.2; 81.2] p < .0001
Female -2.5 [-4.5; -0.5] p < 0.0156
Low educational (primary or less) -7.3 [-9.6; -5.1] p < .0001
BMI > 30 (kg/m2) -4.6 [-7.4; -1.7] p < 0.0021
Unemployment -7.2 [-9.4; -5.1] p < .0001
Duration of dialysis > 3 years -2.5 [-4.7; -0.4] p < 0.0226
Hospitalization in the last 4 weeks -5.2 [-8.6; -1.8] p < 0.0029
Critical illness in the last 4 weeks -6 [-10.6; -1.4] p < 0.0110
Side effects related to general health -9.8 [-12.5; -7] p < .0001
Side effects related to mental health -6 [-8.7; -3.3] p < .0001
Side effects related to body modification -4.4 [-6.6; -2.2] p < .0001
MH R2 = 0.27 Intercept 87 [84.1; 89.9] p < .0001
Female -4.1 [-6.1; -2.2] p < .0001
Family status (living alone) -8.1 [-10.3; -5.8] p < .0001
Dismissal -3.7 [-6.7; -0.7] p < 0.0152
Duration of dialysis > 3 years -3.9 [-5.9; -1.8] p < 0.0003
Hospitalization in the last 4 weeks -5.1 [-8.3; -2] p < 0.0014
Recent surgery -10.3 [-18.2; -2.4] p < 0.0107
Side effects related to general health -6.4 [-9.1; -3.7] p < .0001
Side effects related to mental health -10.2 [-12.8; -7.5] p < .0001
Side effects related to body modification -3.7 [-5.9; -1.6] p < 0.0007
MC R2 = 0.1 Intercept 79.2 [78; 80.5] p < .0001
Family status (living alone) -3.8 [-5.9; -1.7] p < 0.0004
Dismissal -3.1 [-6; -0.2] p < 0.0354
Side effects related to general health -5.9 [-8.4; -3.3] p < .0001
Side effects related to mental health -3.6 [-6.1; -1] p < 0.0056
Side effects related to body modification -2.9 [-4.9; -0.8] p < 0.0057
TR R2 = 0.31 Intercept 77.4 [76.4; 78.4] p < .0001
BMI > 30 (kg/m2) -3.2 [-5.3; -1.1] p < 0.0030
Non-compliant -4.4 [-6.1; -2.7] p < .0001
Side effects related to general health -9.5 [-11.5; -7.5] p < .0001
Side effects related to mental health -6.8 [-8.8; -4.8] p < .0001
Side effects related to body modification -7.5 [-9.1; -5.9] p < .0001
FG R2 = 0.1 Intercept 66.5 [62.3; 70.7] p < .0001
Female -3 [-5.8; -0.1] p < 0.0409
Side effects related to mental health -11.4 [-15.1; -7.7] p < .0001
Side effects related to body modification -4.9 [-7.9; -1.8] p < 0.0016
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http://www.hqlo.com/content/11/1/88Health Surveillance made it a priority to conduct spe-
cific actions for professional reintegration, related to
their plan to improve the quality of life of chronic dis-
ease patients.
In accordance with other studies, comorbidities like a
BMI over 30, the presence of diabetes, the duration of
dialysis and the smoking status reduced the quality oflife in almost all dimensions, but intercurrent events of
health also have a negative influence on the HRQOL in
all dimensions [46-48]. Among intercurrents events,
having been hospitalized in the last 4 weeks, having an
infectious disease and a critical illness in the last 4 weeks,
and having a recent surgery on the graft are associated
with a lower HRQOL.
Figure 1 Matrix diagram for SF36.
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http://www.hqlo.com/content/11/1/88Our results also emphasized the negative impact of
treatment [49,50]. We found that compliance and side
effects were associated with very low scores [51], in every
dimension and regardless of the measurement instrument
used [52-54]. These results could be explained by the lack
of information received concerning possible side effects,
and the extreme importance of the treatment schedule
[55]. Perhaps the duration of doctor’s visits could be lon-
ger or more frequent, with specific health education about
treatment including how the drugs must be taken and ad-
hered to, treatment benefits, and side effects. Then, med-
ical staff could propose specific programs to patients to
handle the difficulties due to specific treatment, using a
medical booklet regarding their treatment [56]. Thus, the
French Biomedicine Agency and the National Health In-
stitute for Public Health Surveillance have recommended
a program for specific health education of RTR [57].Concerning ReTransQol specific dimensions, the phys-
ical aspects of HRQOL of RTR have been reported as
impaired. Physical restrictions are mostly associated with
the frequent occurrence of comorbidities and side effects
of immunosuppressive therapy [58,59]. However, we can
observe that the ReTransQol specifically showed that
medical variables are responsible for worsening health,
especially the 3 main factors which are exclusively treat-
ment side effects. Our study pointed out that older age
has a positive influence on the fear of losing the graft
dimension (β coeff. = −10 points for age < 75 years).
Indeed, elderly patients were less anxious about the fear
of losing their graft.
We can consider that the ReTransQol is more sensi-
tive than SF-36 for health status variables, but less ex-
haustive for socio-demographic factors. Finally, it could
be very interesting to work with both, because these
Figure 2 Matrix diagram for RTQ.
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http://www.hqlo.com/content/11/1/88tools are complementary and offer different views on
HRQOL for RTR [60]. Limitations of our research are
related to the study design (cross-sectional), so we can-
not truly interpret predictive factors. A cohort study or
panel study would allow us to analyze risk factors and
use correlations to determine absolute predictive factors.
However, this study is currently repeated under the same
conditions to compare scores and its evolution over
time.
Conclusion
The clinical relevance of this study lies in demonstrating
that comorbidities frequently occur as side effects of im-
munosuppressive therapy, such as hypertension and dia-
betes, which are associated with physical aspects of theHRQOL after renal transplantation. Therefore, the oc-
currence of these side effects should be taken into ac-
count in the choice of the renal replacement therapy
(dialysis or transplantation). In addition, it is possible
that public policies directed toward vocational rehabilita-
tion may lead to positive effects in mental HRQOL.
Intervention to improve mental HRQOL on personal
factors indirectly related to health may increase the
probability of professional rehabilitation, with personal
as well as socioeconomic advantages. A better under-
standing of the role of personal factors is essential in the
development of psychosocial interventions to maximize
HRQOL. Given that treatment side effects negatively im-
pact every level of HRQOL, we recommend a better med-
ical follow-up of side effects, considering specificities
Gentile et al. Health and Quality of Life Outcomes 2013, 11:88 Page 11 of 12
http://www.hqlo.com/content/11/1/88related to gender. Having a professional activity seems to
be a major element in improving the HRQOL of RTR.
These actions are integrated into the national HRQOL im-
provement plan in France. Repetition of this study is ne-
cessary to measure the impact of actions, and is now
underway with a larger sample including more than 20 re-
gions in France.
Summary
This study aims to identify factors associated with health
related quality of life (HRQOL) through a comprehen-
sive analysis of sociodemographic and clinical variables
among a representative sample size of renal transplant
recipients in France.
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